top of page

Cleerly is a pioneering digital healthcare enterprise specializing in addressing heart disease. At its core, Cleerly offers a cutting-edge AI-powered digital care platform designed to collaborate with coronary computed tomography angiography (CCTA) imaging. This innovative platform empowers healthcare professionals to detect and characterize atherosclerosis at an earlier stage, facilitating the creation of tailored treatment strategies. By precisely assessing atherosclerosis, which refers to the accumulation of plaque in the arteries of the heart, Cleerly's platform streamlines the process of evaluating and reporting heart disease, providing a simpler, swifter, and more precise approach. Established in 2017 and headquartered in New York, New York, Cleerly is at the forefront of revolutionizing cardiac care.

Founding Investor (June 2017) alongside Dalio Foundation at a $20M valuation (F&F Round)

Subsequent Additional Investments in Rounds A, B, C and Common. 
 

Recent News & Awards:

* 2026 January: Aetna, a CVS Health Company, covering more than 20 million lives, now joins UnitedHealthcare, Cigna, and Humana in providing coverage for Cleerly LABS plaque Analysis

* 2026 January: Cleerly's AI-enabled plaque analysis can be billed using Category I CPT Code 75577.  Category I designation signals that this procedure is no longer experimental.

* 2025 October: Coverage by UnitedHealthCare & Cigna begins.  Multiple Benefits Managers also updating coverage guidelines to include Cleerly.

* 2025 April: Heathcare Technology Report names Cleerly to the "Top 25 Healthcare AI Companies of 2025."
 
* 2024: The validation paper for Cleerly ISCHEMIA has been recognized as one of the TOP 5 most read and discussed papers of 2024 in JACC Journals: Cardiovascular Imaging

* 2024 December: Insight Partners invests $106,000,000

* 2024 October: Received approval of a CPT Category I code and also the expansion of Medicare coverage

* 2024: Four of the seven Medicare Administrative Contractors (MACs) in the United States have approved coverage for Cleerly's Al-powered coronary CTA plaque analysis for patients with symptomatic stable and acute chest pain and who are found to be intermediate risk or have a 1-69% stenosis (CAD-RADs 1-3).  This coverage will go into effect November 24, 2024 for all Medicare recipients in the 24 States represented by Palmetto, CGS, WPS and NGS.

* 2024: James Min, MD, Named to Top 50 MedTech Entrepreneurs

* 2024 1Q: ISCHEMIA Software device receives AMA Category CPT Code

* 2024: James Min, MD, Founder & CEO of Cleerly, recognized by Business Insider as one of the Top 10 People in AI Healthcare

* 2024: Business Insider "25 Healthcare Startups Set To Take Off in 2024"

* 2023: CB Insights: Digital Heath 50

* 2023: Winner of Best Use of AI in Health Tech Award beating out 1,000+ nominations. UCSF Digital Health Hub Award

* July 2022: $192M C-Round with Peter Thiel, Cigna Ventures, T. Rowe Price, Fidelity Investments, among others for a post-money valuation of $665M. 

* 2022 - Fast Company Honorable Mention in AI & Data Category "World-Changing Ideas Awards" 

bottom of page